Patients with atrial fibrillation who take common analgesics can significantly increase their risk for bleeding and thromboembolism, with risk higher among those on anticoagulation who also take a nonsteroidal anti-inflammatory drug, according to a new study published in the Nov. 18 issue of the Annals of Internal Medicine.
With an aging population, clinicians must guard against potential complications and adverse events brought on by treatment. For example, a recent study appeared to show that overtreatment with anticoagulants increases dementia risk in patients with atrial fibrillation.
Overtreatment with anticoagulation for atrial fibrillation may double risk for dementia, a new study suggests. The study findings are being presented at the annual meeting of the American Heart Association, held from Nov. 15 to 19 in Chicago.
Analysis of insurance claims and medical records indicates that people with mitral annular calcification may face a greatly elevated risk of incident atrial fibrillation.
Though warfarin has long been the mainstay of anticoagulation in atrial fibrillation (AF), dosing is complicated by a host of factors, and the drug has a famously narrow therapeutic range. One way to fine-tune warfarin therapy is to account for genetic variation.
Anticoagulation is recommended for members of the general population with atrial fibrillation, but its significant risks must be weighed carefully in the medically fragile chronic kidney disease population.